Published in Blood Weekly, May 29th, 2003
Theralux is Celmed's photodynamic therapy (PDT) technology being developed to destroy cancer cells in bone marrow or blood outside the body (ex vivo), using a proprietary drug, TH9402, which selectively kills cancer cells when exposed to light.
Orphan drug designation is granted to products that have the potential to treat life-threatening diseases that affect fewer than...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.